Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
Open accessAbstract
UNLABELLED: This study aimed at identifying clinical factors for predicting hematologic toxicity after radioimmunotherapy with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab in clinical practice. METHODS: Hematologic data were available from 14 non-Hodgkin lymphoma patients treated with (90)Y-ibritumomab tiuxetan and 18 who received (131)I-tositumomab. The percentage baseline at nadir and 4 wk post nadir and the time to nadir were selected as the toxicity indicators for both platelets and neutrophils. Multiple linear regression analysis was performed to identify significant predictors (P < 0.05) of each indicator. RESULTS: For both platelets and neutrophils, pooled and separate analyses of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab data yielded the time elapsed since the last chemotherapy as the only significant predictor of the percentage baseline at nadir. The extent of bone marrow involvement was not a significant factor in this study, possibly because of the short time elapsed since the last chemotherapy of the 7 patients with bone marrow involvement. Because both treatments were designed to deliver a comparable bone marrow dose, this factor also was not significant. None of the 14 factors considered was predictive of the time to nadir. The R(2) value for the model predicting percentage baseline at nadir was 0.60 for platelets and 0.40 for neutrophils. This model predicted the platelet and neutrophil toxicity grade to within ±1 for 28 and 30 of the 32 patients, respectively. For the 7 patients predicted with grade I thrombocytopenia, 6 of whom had actual grade I-II, dosing might be increased to improve treatment efficacy. CONCLUSION: The elapsed time since the last chemotherapy can be used to predict hematologic toxicity and customize the current dosing method in radioimmunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with lymphoma receiving a relatively standard bone marrow radiation-absorbed dose from radioimmunotherapy, the duration of time postchemotherapy was the most strongly correlated factor with the severity of myelosuppression.
“In patients with lymphoma receiving a relatively standard bone marrow radiation-absorbed dose from radioimmunotherapy, the duration of time postchemotherapy was the most strongly correlated factor with the severity of myelosuppression ( 106 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T. A., Stagg, R., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 585 · see citing works
Self-citationWitzig, T. E., White, C. A., Wiseman, G. A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 541 · see citing works
Vose, J. M., Wahl, R. L., Saleh, M. N., Rohatiner, A. Z. S., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 360 · see citing works
Self-citationWitzig, T. E., White, C. A., Gordon, L. I., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.043 · Cited by 289 · see citing works
Horning, S. J., Younes, A., Jain, V. K., Kroll, S., Lucas, J. B., Podoloff, D. A., & Goris, M. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 259 · see citing works
Wiseman, G. A., Kornmehl, E., Leigh, B. R., et al. (2003) · PubMed · Cited by 218 · see citing works
Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C. E., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R. M., Vo, K., & Wiseman, G. A. (2007) · Cancer · doi:10.1002/cncr.22617 · Cited by 176 · see citing works
Rationales, evidence, and design considerations for fractionated radioimmunotherapy
DeNardo, G. L., Schlom, J., Buchsbaum, D. J., et al. (2002) · Cancer · doi:10.1002/cncr.10304 · Cited by 129 · see citing works
Wahl, R. L., Kroll, S. M., & Zasadny, K. R. (1998) · PubMed · Cited by 117 · see citing works
Self-citationComparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
Jacene, H. A., Filice, R. W., Kasecamp, W., & Wahl, R. L. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043489 · Cited by 102 · see citing works
Self-citationRadioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
Davies, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210378 · Cited by 94 · see citing works
Fisher, D. R., Shen, S., & Meredith, R. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057331 · Cited by 88 · see citing works
Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components
Sgouros, G., Stabin, M. G., Erdi, Y. E., Akabani, G., Kwok, C., Brill, A. B., & Wessels, B. W. (2000) · Medical Physics · doi:10.1118/1.1288393 · Cited by 79 · see citing works
Self-citationSiegel, J. A., Yeldell, D., Goldenberg, D. M., et al. (2003) · PubMed · Cited by 68 · see citing works
Wahl, R. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.23799 · Cited by 57 · see citing works
Self-citationO'Donoghue, J. A., Baidoo, N., Deland, D., Welt, S., Divgi, C. R., & Sgouros, G. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802760363222 · Cited by 55 · see citing works
Self-citationBouček, J., & Turner, J. H. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1692-9 · Cited by 52 · see citing works
Wahl, R. L. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70055-4 · Cited by 49 · see citing works
Self-citationJuweid, M. E., Zhang, C. H., Blumenthal, R. D., et al. (1999) · PubMed · Cited by 35 · see citing works
Gregory, S. A., Leonard, J. P., Knox, S. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.6732 · Cited by 13 · see citing works
Pharmacodynamic analysis of hematologic profiles
Rosner, G. L., & Müller, P. (1994) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353792 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A bone marrow toxicity model for <sup>223</sup> Ra alpha-emitter radiopharmaceutical therapy
Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K., Ramdahl, T., Flux, G. D., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/10/3207 · Cited by 122 · see citing works
Self-citationNormal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works
Self-citation
- Authors
- Baechler, S., Hobbs, R. F., Jacene, H. A., Bochud, F. O., Wahl, R. L., & Sgouros, G.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Johns Hopkins University (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-11-23
- Volume
- 51
- Issue
- 12
- Pages
- 1878-1884
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC3169802
- OpenAlex
- W2136442484
- Cited by
- 36
- References
- 21
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 3 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 6
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Funders
- National Science Foundation
- GlaxoSmithKline
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (115886)
- National Institutes of Health
- National Cancer Institute (R01CA116477)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- hematologic toxicity, radioimmunotherapy, yttrium-90 ibritumomab tiuxetan, iodine-131 tositumomab, non-Hodgkin lymphoma, thrombocytopenia, neutropenia, bone marrow involvement, toxicity prediction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Bone Marrow, Female, Hematologic Diseases, Humans, Leukocyte Count, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neutrophils, Platelet Count, Predictive Value of Tests, Radiometry, Thrombocytopenia, Yttrium Radioisotopes, Models, Statistical, Linear Models, Radioimmunotherapy, Drug Resistance, Neoplasm, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
